Medscape7d
Novel Once-Daily Cystic Fibrosis Treatment Matches Standard Therapy in Phase 3 Trials
A novel once-daily drug showed a comparable efficacy and safety profile as the standard-of-care drug in patients with cystic ...
Sionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis Treatments
Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...
BlackDoctor1d
When Cystic Fibrosis Hits the Lungs, HIT BACK
When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...
Can you get disability benefits for cystic fibrosis? 3 things to do if your claim is denied
If you receive a denial letter from your insurer, don’t appeal the decision before seeking legal advice, says a leading ...
Woman with cystic fibrosis to embark on 3,200 mile row across Atlantic Ocean in historic world-first
Sophie would make a world record for being the first man or woman with cystic fibrosis to row across the Atlantic, while at ...
Vertex Pharmaceuticals' SWOT analysis: strong CF franchise fuels pipeline stock growth
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...
Healio6d
Vanzacaftor, tezacaftor, deutivacaftor safe in children with cystic fibrosis
Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...
Independent.ie3d
‘Time is precious’ – children with rare cystic fibrosis gene denied access to potentially life-extending therapies
Children whose cystic fibrosis is caused by a rare gene variant are excluded from a new treatment which could potentially ...
imt.ie5d
Call for children with cystic fibrosis and rare genes to gain access to life-saving therapy
Some people with cystic fibrosis still do not have access to the life-changing modulator therapy drugs, despite wider EMA ...
Glox Therapeutics Awarded Share of £3M Collaborative Discovery Programme Funding from Cystic Fibrosis Antimicrobial Resistance Syndicate
K grant to accelerate development of Glox Therapeutics' novel precision antibiotics targeting AMR lung infections in people ...